文献速递胸部肿瘤放疗放疗物理与技术

非小细胞肺癌放射性食管炎剂量模式与剂量学预测因素的外部验证

External Validation of Dose Patterns and Dosimetric Predictors for Radiation-Induced Esophagitis In Non-Small Cell Lung Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-07-31

基于RTOG-0617试验495例中326例非小细胞肺癌患者数据,外部验证了放射性食管炎(RE)的剂量模式与剂量学预测因素。体素分析确认上中段食管为RE2+显著关联区域,与既往研究重叠度良好(Dice-over-volume=0.7);食管V55Gy和上中段食管平均剂量均为良好预测因素,后者校准精度更优。

要点

  • 上中段食管是RE2+风险的关键区域,体素分析结果在独立队列中获验证。
  • 上中段食管平均剂量预测RE2+的区分度AUC=0.70(95%CI 0.61-0.72)。
  • 上中段食管平均剂量校准精度优于食管V55Gy(Radj² 0.80 vs 0.65)。

核心结论

  • 体素分析关于放射性食管炎的发现已在独立非小细胞肺癌队列中成功验证,上中段食管为RE2+风险关键区域。
  • 上中段食管平均剂量在不同治疗技术和患者特征下均为稳健预测因素。

研究设计与样本

  • 分析RTOG-0617试验患者数据,患者接受同步化疗联合或不联合西妥昔单抗及60 Gy与74 Gy放疗剂量。
  • 495例患者中326例符合分析纳入标准。

主要发现

  • RE2+发生率为44%,与开发队列一致。
  • 临床因素与RE2+无显著相关。
  • 体素分析识别出上中段食管生物有效剂量与RE2+关联最显著区域,与既往研究重叠度Dice-over-volume=0.7。
  • 食管相对体积接受≥55 Gy(V55Gy)与上中段食管平均剂量均在外部队列中确认为良好预测因素,区分度AUC=0.70(95%CI 0.61-0.72)。
  • 校准曲线显示上中段食管平均剂量风险预测精度更优(Radj² 0.80 vs 0.65)。

关键数值与推荐

  • RE2+定义为≥2级放射性食管炎。
  • 食管V55Gy指食管相对体积接受≥55 Gy。
  • 上中段食管平均剂量预测RE2+的AUC=0.70(95%CI 0.61-0.72),校准Radj²=0.80。
  • 食管V55Gy预测RE2+的校准Radj²=0.65。

临床怎么用

  • 可将上中段食管平均剂量作为RE2+风险的稳健剂量学预测指标用于临床评估。
  • 体素分析结果可为放射性食管炎风险区域的临床实施提供基础。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation-induced esophagitis (RE) is a dose-limiting complication associated with chemo-radiation therapy for non-small cell lung cancer (NSCLC). We aimed to externally validate dose patterns and dosimetric predictors of grade ≥ 2 RE (RE2+) in an independent NSCLC cohort. METHODS AND MATERIALS: We analyzed Radiation Therapy Oncology Group-0617 trial patient data. Patients received concurrent chemotherapy with or without cetuximab and 60- versus 74-Gy radiation doses. Voxel-based analysis (VBA) assessed spatial dose differences between patients with and without RE2+. The generalized linear model included dose maps and each nondosimetric variable selected by a least absolute shrinkage and selection operator regularized generalized linear model of RE2+. A nonparametric permutation test of the maximum threshold-free cluster-enhanced statistic accounting for multiple comparisons was performed, and the significance p-maps were generated and compared using the Dice-over-volume metric with previous VBA results. The external validity of esophageal predictors was also assessed in terms of discrimination (the area under the receiver's operating characteristic curve value) and calibration. RESULTS: Out of 495 patients, 326 met the inclusion criteria for analysis. The RE2+ incidence (44%) was consistent with the development cohort. Clinical factors were not significantly correlated with RE2+. VBA identified the most significant regions of associations between biologically effective dose and RE2+ in the upper and middle thoracic esophageal (UME) segment, with satisfactory overlap with a prior study (Dice-over-volume metric = 0.7). The relative esophageal volume receiving ≥ 55 Gy (V55Gy) and the UME mean dose (Dmean) were both confirmed as good predictors in external validation with comparable discrimination (area under the curve value = 0.70; 95% CI: (0.61-0.72)). Calibration curves indicated superior risk prediction accuracy for UME-Dmean (Radj2, 0.80 vs 0.65). CONCLUSIONS: We successfully validated VBA findings on RE in an independent NSCLC cohort, reinforcing the role of the upper-middle esophagus as a critical region for RE2+ risk. The UME-Dmean emerged as a robust predictor across diverse treatment techniques and patient characteristics. These findings provide a foundation for clinical implementation of VBA.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Monti S, Palma G, Caroprese M, et al. External Validation of Dose Patterns and Dosimetric Predictors for Radiation-Induced Esophagitis In Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2025. PMID: 40752651. doi:10.1016/j.ijrobp.2025.07.1445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。